TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Oct 13, 2022 23:34 JST
Source:
Essex Bio-Technology Limited
亿胜生物成功从Mitotech获得SkQ1眼科领域全球独家权益
香港, Oct 13, 2022 - (ACN Newswire) - 亿胜生物科技有限公司(“亿胜生物”,连同其附属公司统称“本集团”)欣然宣布,本集团全资附属公司Essex Bio-Investment Limited(“Essex Bio-Investment”)与Mitotech S.A.(“Mitotech”)已于2022年10月13日订立与SkQ1(一种活性药物成分)相关的(i)专利及专有技术许可协议及(ii)专利转让契据,二者统称“协议”。在该协议中,Mitotech授予本集团在全球范围内(不包括亚美尼亚、白俄罗斯、哈萨克斯坦、吉尔吉斯斯坦及俄罗斯) (“全球”)的SkQ1眼科领域的可转让和不可撤销的独家权益。
根据协议,Mitotech已同意向Essex Bio-Investment转让发明和专利清单等所有权利,并授予包括独家、可转让和不可撤销的全球许可,以(无附带产权负担地)使用Mitotech拥有的与SkQ1相关的专利开发、制造、销售及供应适用于眼睛及其附属器官的任何治疗产品或疗法(“产品”),申请及获得临床试验的全球监管批准,并获得与产品相关的市场推广授权。
协议签署后,Essex Bio-Investment、Mitotech及Mitotech LLC于2022年10月13日就2018年7月16日订立的共同开发协议(“共同开发协议”)订立第四份补充协议。在该协议中,Mitotech LLC及Mitotech将放弃与美国药监局VISTA计划(有关含有SkQ1的滴眼液治疗干眼症的临床研究,“VISTA计划”)相关的所有及任何权利。
董事会认为,获得与SkQ1相关的协议乃对本集团于干眼症领域的VISTA计划的持续发展提供灵活性及独立性的重要措施,并将使本集团能够进一步探索开发其他适应症的眼科产品,以满足全球市场的临床及商业需求。本协议符合集团及股东的整体利益。
关于Mitotech
Mitotech S.A.是一家总部位于卢森堡的临床阶段生物技术公司,主要开发治疗老龄化相关性疾病创新药物。Mitotech的产品核心技术基于一类新型小分子——靶向线粒体心磷脂过氧化的抑制剂。公司先导化合物SkQ1目前正处于一系列药物剂型的开发中,覆盖多个疾病治疗领域,其中以眼科和神经退行性疾病为主。
关于SkQ1
SkQ1通过一种创新的机制在细胞水平上作用于线粒体,达到治疗干眼症的目的。不同于与现行多数采用抗炎机制的治疗手段,SkQ1通过靶向阻断眼部氧化应激反应,不仅减轻眼部炎症反应,也可以改善眼表组织退化、泪液质量下降等问题。目前,VISTA计划(SkQ1滴眼液治疗干眼症的临床研究)已进展到美国3期临床阶段,VISTA-1——一项在美国开展的2b/3期临床试验(NCT03764735)及VISTA-2——一项在美国开展的3期临床试验(NCT04206020)均显示,SkQ1能有效改善干眼症受试者的眼部症状及体征。此外,SkQ1在治疗干性AMD(老年性黄斑变性)、LHON(遗传性视神经病)、青光眼及葡萄膜炎的研究处于临床前期阶段。
关于亿胜生物(股份代码: 1061.HK)
亿胜生物科技有限公司是一间专注于研发,生产和销售基因工程药物b-bFGF(FGF-2)的生物制药企业,自1998年起已有六种基因工程药物在中国上市销售。此外,公司还拥有一系列不含防腐剂单剂量滴眼液和适丽顺®(卵磷脂络合碘胶囊)等产品。公司产品主要应用于眼科及皮肤科处方药领域的创伤修复及疾病治疗,目前凭借在中国主要城市的43个销售推广办事处已成功覆盖中国逾10,710家医院。公司依托自身在生长因子和抗体领域的研发平台,拥有多个临床阶段的项目,涵盖广泛的领域和适应症。
集团网站:
http://www.essexbio.com
传媒查询:
纵横财经公关顾问有限公司(网址:
http://www.sprg.com.hk
)
郑松雪 +852 2864 4857
shelly.cheng@sprg.com.hk
司徒可雯 +852 2864 4859
holly.szeto@sprg.com.hk
张锶婷 +852 2864 4870
jill.cheung@sprg.com.hk
媒体关系media@essex.com.cn
投资者查询:
投资者关系investors@essex.com.cn
Source: Essex Bio-Technology Limited
Sectors: BioTech, Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Related Press Release
Essex Bio-Technology Posts Sound 2023 Annual Financial Results, Revenue Up 29.5%, Profit Up 22.1%
March 18 2024 21:30 JST
Essex Bio-Technology Posts Sound 2023 Interim Financial Results, Revenue Up 37.1%, Profit Up 22%
August 16 2023 19:06 JST
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed
July 26 2023 18:58 JST
Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore
April 14 2023 17:18 JST
Essex and Gunze Shenzhen Entered into Exclusive Agency Agreement for PELNAC Absorbable Dressing in Mainland China
April 11 2023 12:58 JST
Essex Bio-Technology Announces 2022 Annual Financial Results
March 08 2023 20:28 JST
Essex and Henlius signed amendment agreement for Global Co-Development and Exclusive License Agreement for treatment of age-related macular degeneration
February 22 2023 18:48 JST
First Patient in the US Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases
February 10 2023 21:06 JST
Essex Biotechnology Secures Exclusive Rights and Interests in SkQ1 for Ophthalmology from Mitotech
October 13 2022 22:40 JST
Essex Bio-Technology Included in "Forbes Asia's Best Under A Billion 2022"
August 16 2022 09:00 JST
More Press release >>
Latest Press Release
TANAKA Precious Metals Announces Executive Appointments
Sep 07, 2024 03:00 JST
Panasonic Energy and Mazda to Begin Preparation for Supply of Automotive Lithium-ion Batteries
Sep 06, 2024 16:34 JST
Toyota's Next-Generation BEV Battery Development and Production Plan Certified by METI
Sep 06, 2024 15:10 JST
Toyota Motor Corporation and BMW Group Strengthen Collaboration Towards the Advancement of a Hydrogen Society
Sep 06, 2024 09:26 JST
DENSO Fukushima Launches Production of Inverters
Sep 05, 2024 17:41 JST
Eisai Accelerates Progress in Oncology Research with New Data at ESMO Congress 2024
Sep 05, 2024 16:59 JST
Launch of IOWN Network Solution for 400Gbps High-Speed Inter-Data Center Connections that Reduces Construction and Operation Costs by 50%, and power consumption by 40%
Sep 05, 2024 11:58 JST
Fujitsu and MoBagel revolutionize business processes through accelerated AI prediction
Sep 05, 2024 10:40 JST
Hitachi Develops a Model of BuilMirai Building IoT Solution for Small and Medium-Sized Buildings to Strengthen Green & Smart Building Business
Sep 04, 2024 12:22 JST
Seven Companies Announce to Conduct Engineering Design Work for Japanese Advanced CCS (Carbon Capture and Storage) Project
Sep 04, 2024 11:46 JST
MHI and Mitsubishi Logisnext to Display "SigmaSynX" Products Enabling Autonomous and Intelligent Warehouse Logistics
Sep 04, 2024 09:48 JST
Cisgenics Brings Next-Generation Irrigation Technology to Australia
Sep 03, 2024 13:29 JST
NEC Launches new system using Biometric Authentication Technology
Sep 03, 2024 10:38 JST
Terrific Texas fight back from TOYOTA GAZOO Racing
Sep 02, 2024 17:09 JST
Eisai Announces Status Relating to Acquisition of Own Shares
Sep 02, 2024 15:12 JST
TANAKA Memorial Foundation to Offer Precious Metals Research Grants of Up to 10 Million Yen (from a Grant Pool of 20 Million Yen)
Sep 02, 2024 11:00 JST
Fujitsu establishes Open All-Photonics Network Lab in Europe to promote global expansion of innovative network infrastructure
Aug 30, 2024 18:15 JST
JCB and Permata Launch the Permata JCB Ultimate Card
Aug 30, 2024 17:00 JST
JCB and BINDO Launch World's First Metal JCB Card
Aug 30, 2024 17:00 JST
Intercity Battery Train Starts Testing in the North of England
Aug 29, 2024 19:20 JST
More Latest Release >>